With breast cancer cases rising sharply in India and studies indicating a significant proportion still going undetected in routine screening, clinicians are underlining the urgent need for advanced ...
(RTTNews) - Becton, Dickinson and Co. (BDX) today announced that the U.S. FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System, a next-generation device ...
The U.S. Food and Drug Administration on Thursday granted 510(k) clearance for Becton, Dickinson and Company’s (NYSE: BDX) new breast biopsy system. The FDA approved BD’s EnCor EnCompass Breast Biopsy ...
State-of-the-art, multi-modality breast biopsy system slated to be in the market in early 2026 FRANKLIN LAKES, N.J., Jan. 15, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a ...
Omitting SLNB in older patients with early-stage, HR-positive, HER2-negative breast cancer showed similar safety and efficacy to performing the procedure. The BOOG 13-08 trial demonstrated comparable ...
SAN ANTONIO -- Many patients with early breast cancer can safely skip sentinel lymph node biopsy (SLNB), results of a large Dutch study suggested. After 5 years, the regional recurrence-free survival ...
Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...
Omitting sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer undergoing breast-conserving surgery may not increase the risk for recurrence over 5 years, according to findings ...
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...
SAN ANTONIO – Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional ...
Please provide your email address to receive an email when new articles are posted on . Armando E. Giuliano, MD, will receive the 2025 William L. McGuire Memorial Lecture Award. Giuliano is being ...